Milbank IP and Litigation partner John Lu spoke on a panel titled “Global Patent Issues of Therapeutic Antibodies” at the fourth annual China Pharma IP Summit on October 24, 2019 in Shanghai, China.
Topics of the panel included:
- PD-1/PD-L1 patent landscape in the US, Europe and China
- Challenges of obtaining global patent protection over antibody inventions
- Enhancing the value of antibody inventions
- Life cycle management of therapeutic antibody products
Mr. Lu joined Milbank in August 2019. His practice focuses on patent litigation and life sciences matters. He has represented clients in matters involving patent infringement, biosimilars, ANDA litigation and licensing disputes. Mr. Lu also represents clients in connection with proceedings before the Patent Trial and Appeal Board. His prior life sciences industry clients have included Genentech, Biogen, Gilead Sciences and Santarus (now Salix Pharmaceuticals).
To learn more about the China Pharma IP Summit please click here.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
